Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Non Operating Income (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Non Operating Income for 11 consecutive years, with $190000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 171.43% to $190000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $345000.0 through Dec 2025, down 26.91% year-over-year, with the annual reading at $345000.0 for FY2025, 26.91% down from the prior year.
  • Non Operating Income hit $190000.0 in Q4 2025 for Aptevo Therapeutics, up from $61000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $230000.0 in Q2 2023 to a low of -$2.6 million in Q4 2021.
  • Historically, Non Operating Income has averaged -$532000.0 across 5 years, with a median of $41500.0 in 2025.
  • Biggest five-year swings in Non Operating Income: tumbled 58650.0% in 2021 and later surged 1008.0% in 2023.
  • Year by year, Non Operating Income stood at -$2.6 million in 2021, then skyrocketed by 100.82% to $21000.0 in 2022, then soared by 795.24% to $188000.0 in 2023, then crashed by 62.77% to $70000.0 in 2024, then surged by 171.43% to $190000.0 in 2025.
  • Business Quant data shows Non Operating Income for APVO at $190000.0 in Q4 2025, $61000.0 in Q3 2025, and $22000.0 in Q2 2025.